| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/12/2012 | US20120010259 Methods of Treating an Overweight or Obese Subject |
| 01/12/2012 | US20120010257 Modulators of cystic fibrosis transmembrane conductance regulator |
| 01/12/2012 | US20120010256 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 01/12/2012 | US20120010247 Bicyclic compound |
| 01/12/2012 | US20120010232 Compositions for affecting weight loss |
| 01/12/2012 | US20120010211 Pharmaceutical composition for treatment of type 2 diabetes |
| 01/12/2012 | US20120010203 Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments |
| 01/12/2012 | US20120010197 Protein kinase inhibitors |
| 01/12/2012 | US20120010192 Fused Heterocyclic Compounds as Ion Channel Modulators |
| 01/12/2012 | US20120010190 1-hydroxyimino-3-phenyl-propanes |
| 01/12/2012 | US20120010189 (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds |
| 01/12/2012 | US20120010188 Imidazopyridine Compounds |
| 01/12/2012 | US20120010186 Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 01/12/2012 | US20120010185 New pyridone derivates with mch antagonistic activity and medicaments comprising these compounds |
| 01/12/2012 | US20120010160 Rapidly Dissolving Oral Strip of Sugar for Hypoglycemia |
| 01/12/2012 | US20120010156 Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
| 01/12/2012 | US20120010137 Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer |
| 01/12/2012 | US20120010136 Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders |
| 01/12/2012 | US20120010135 Spiro derivatives for the modulation of stearoyl-coa desaturase |
| 01/12/2012 | US20120010123 Methods of treating metabolic disorders and cardiovascular diseases |
| 01/12/2012 | US20120009273 Kit of pharmaceutical formulations characterized by the presence of molecular oxygen |
| 01/12/2012 | US20120009269 Range of aseptically produced infant foods having low concentrations of undesired by-products and methods for making the same |
| 01/12/2012 | US20120009268 Modified Virus Vectors and Methods of Making and Using the Same |
| 01/12/2012 | US20120009260 Nanoparticle film delivery systems |
| 01/12/2012 | US20120009259 Formulation for co-therapy treatment of diabetes |
| 01/12/2012 | US20120009244 NEUROD1 GENE EXPRESSION IN NON-ENDOCRINE PANCREATIC EPITHELIAL CELLS (NEPECs) |
| 01/12/2012 | US20120009239 Prebiotic Formulations for use with Probiotics to Increase Probiotic Growth Rate and Activity |
| 01/12/2012 | US20120009226 Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| 01/12/2012 | US20120009196 Monoclonal antibodies against hepatitis c virus core protein |
| 01/12/2012 | US20120009171 Methods and compositions for cns delivery of arylsulfatase a |
| 01/12/2012 | US20120009168 Improved emulsifying system for nutraceutical compositions |
| 01/12/2012 | US20120009165 Blood-adiponectin-concentration increase-accelerator and/or decrease-inhibitor thereof and visceral fat accumulation inhibitor |
| 01/12/2012 | US20120006716 Humanized anti-il-6 antibodies |
| 01/12/2012 | CA2805313A1 Use of deuterium depleted water for the treatment of insulin resistance |
| 01/12/2012 | CA2804926A1 Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin |
| 01/12/2012 | CA2804924A1 Substituted pyridine compound |
| 01/12/2012 | CA2804618A1 Stabilized insulinotropic peptides and methods of use |
| 01/12/2012 | CA2804271A1 Prophylactic or therapeutic agent for diabetes |
| 01/12/2012 | CA2804144A1 Multi-component pharmaceuticals for treating diabetes |
| 01/12/2012 | CA2804112A1 (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals |
| 01/12/2012 | CA2803787A1 Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease |
| 01/12/2012 | CA2803580A1 Pharmaceutical compositions including carbamoyloxy arylalkanoyl arylpiperazine compound |
| 01/12/2012 | CA2803448A1 Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators |
| 01/12/2012 | CA2802807A1 Array of age-tailored nutritional formula with optimum fat content |
| 01/11/2012 | EP2404921A1 Salts of tetrahydroimidazo ý1,5-a¨pyrazine derivatives, preparation methods and pharmaceutical use thereof |
| 01/11/2012 | EP2404918A1 Pyridine derivative |
| 01/11/2012 | EP2404909A1 Amide thiazole derivative, preparation method and uses thereof |
| 01/11/2012 | EP2404902A1 Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism |
| 01/11/2012 | EP2404901A1 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
| 01/11/2012 | EP2404896A1 Cyclohexane derivative having npy y5 receptor antagonism |
| 01/11/2012 | EP2404890A1 Hydroxyl compounds and compositions for cholesterol management and related uses |
| 01/11/2012 | EP2404604A1 Salts of potassium ATP channel openers and uses thereof |
| 01/11/2012 | EP2404603A1 Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases |
| 01/11/2012 | EP2404507A1 Array of age-tailored nutritional formula with optimum fat content |
| 01/11/2012 | EP2403854A1 Sulfonylated tetrahydroazolopyrazines and their use as medicinal products |
| 01/11/2012 | EP2403833A1 8-substituted quinolines and related analogs as sirtuin modulators |
| 01/11/2012 | EP2403605A2 Secreted ap2 and methods of inhibiting same |
| 01/11/2012 | EP2403504A1 Pharmaceutical compositions of active pharmaceutical ingredient comprising sulphonylurea moiety with excellent dissolution properties |
| 01/11/2012 | EP2403502A1 Medicinal cosmetic lipoatrophy |
| 01/11/2012 | EP2403491A2 Alkylglycerols and alkoxyglycerols for increasing endogenous plasmalogen levels in mammals |
| 01/11/2012 | EP2173737B1 Method for modulating gpr119 g protein-coupled receptor and selected compounds |
| 01/11/2012 | EP2037928B1 Methods for treating atherosclerosis |
| 01/11/2012 | EP1971339B1 Combination of triazine derivatives and insulin secretion stimulators |
| 01/11/2012 | EP1888066B1 Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 01/11/2012 | EP1885392B1 Insulins combinations |
| 01/11/2012 | EP1868595B1 Compounds for the treatment of metabolic disorders |
| 01/11/2012 | EP1609798A9 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
| 01/11/2012 | EP1569904B1 Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity |
| 01/11/2012 | EP1468092B1 Pim-3 kinase as a target for type 2 diabetes mellitus |
| 01/11/2012 | EP1458687B1 Pyrimidine compounds as interleukin-12 (il-12) inhibitors |
| 01/11/2012 | CN1642542B Angiogenesis inhibitors |
| 01/11/2012 | CN102317320A Fusion protein capable of binding VEGF-A and TNF-alpha |
| 01/11/2012 | CN102317296A Fused aromatic PTP-1B inhibitors |
| 01/11/2012 | CN102317267A Process for the preparation of rosuvastatin salts |
| 01/11/2012 | CN102316934A Nutritional compositions with large lipid globule size |
| 01/11/2012 | CN102316933A Nutritional compositions with large lipid globule size |
| 01/11/2012 | CN102316931A Alkylamido compounds and uses thereof |
| 01/11/2012 | CN102316892A Use of cardiotrophin- 1 for the treatment of metabolic diseases |
| 01/11/2012 | CN102316889A Compositions containing satiogens and methods of use |
| 01/11/2012 | CN102316875A Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabete mellitus, impaired glucose tolerance or hyperglycemia |
| 01/11/2012 | CN102316874A A disintegrating tablet |
| 01/11/2012 | CN102316872A Bile acid recycling inhibitors for treatment of obesity and diabetes |
| 01/11/2012 | CN102316869A Method of treating cancer |
| 01/11/2012 | CN102316861A Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof |
| 01/11/2012 | CN102316856A Pharmaceutical preparation |
| 01/11/2012 | CN102311940A Method for inducing differentiation of stem cells into islet-like cells |
| 01/11/2012 | CN102311868A Method for extracting krill oil rich in phospholipids and neutral lipid without using solvent |
| 01/11/2012 | CN102311501A Fusion protein comprising GLP-1 (Glucagon-Like Peptide) or analog thereof and preparation method as well as application thereof |
| 01/11/2012 | CN102311473A Toonapubesic aldehyde and preparation method as well as application thereof |
| 01/11/2012 | CN102311448A Thieno-pyrimidone DPP-IV (dipeptidyl peptidase) inhibitor |
| 01/11/2012 | CN102311447A Heterocyclo pyrimidone dipeptidyl peptidase-IV (DPP-IV) inhibitor |
| 01/11/2012 | CN102311396A Pyrazine derivative and preparation method as well as application thereof to pharmacy |
| 01/11/2012 | CN102311387A 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| 01/11/2012 | CN102311385A Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity |
| 01/11/2012 | CN102311378A Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related disorders |
| 01/11/2012 | CN102311377A Refining method capable of obtaining atorvastatin calcium in form of crystal |
| 01/11/2012 | CN102309766A Method for improving water solubility of xanthohumol |
| 01/11/2012 | CN102309727A Chinese patent medicine for facial beautification and longevity |
| 01/11/2012 | CN102309705A Medicine for reducing serum uric acid, preparation method thereof and purpose thereof |
| 01/11/2012 | CN102309694A Method for extraction and purification of corn silk general flavone, and use of corn silk general flavone |